

## CHARACTERIZATION OF ENDOTHELIN-1 RECEPTORS IN THE RAT BLADDER BY RADIOLIGAND BINDING ASSAY

### Hypothesis / aims of study

Endothelin (ET)-1 is a 21 amino acid, endogenous vasoactive peptide that binds to two receptor subtypes, namely ET<sub>A</sub> and ET<sub>B</sub> receptor. ET-1 induces prolonged contractile responses in isolated bladder muscle strips in various species [1]. ET-like immunoreactivity was identified in detrusor smooth muscles, epithelium and vascular endothelium [2]. Selective ET<sub>A</sub> receptor antagonists has ameliorating effects on various urinary dysfunctions including benign prostatic hyperplasia [3]. Based on these pharmacological results, the current study aimed to identify directly and characterize ET-1 receptors in the bladder by radioligand binding assay using [<sup>125</sup>I]ET-1 as a selective radioligand of the receptor.

### Study design, materials and methods

Endothelin-1 receptors in the rat bladder homogenates were measured by the radioligand binding assay using [<sup>125</sup>I]ET-1, and binding parameters of apparent dissociation constant ( $K_d$ ) and maximal number of binding sites ( $B_{max}$ ) for [<sup>125</sup>I]ET-1 were estimated by nonlinear regression analysis using Graph Pad Prism. The competitive inhibitory effects of specific [<sup>125</sup>I]ET-1 binding in the rat bladder were measured in the presence of various concentrations of ET-1 and its receptor antagonists (bosentan, ambrisentan and CI-1020). The  $IC_{50}$  representing the molar concentration of agents necessary to displace 50 % of specific [<sup>125</sup>I]ET-1 binding was estimated. Specific [<sup>125</sup>I]ET-1 binding was also comparatively measured in the cerebral cortex, lung, heart and kidney of rats

### Results

Specific binding of [<sup>125</sup>I]ET-1 in the rat bladder homogenates was saturable and of high affinity ( $K_d=110$  pM,  $B_{max}=272$  fmol/mg protein), which characterized a selective labeling of bladder ET-1 receptors. High affinity of specific [<sup>125</sup>I]ET-1 binding was also detected in the cerebral cortex, lung, heart and kidney of rats, and  $K_d$  and  $B_{max}$  values showed some difference among tissues (Table 1). ET-1 and bosentan (a mixed ET<sub>A</sub> and ET<sub>B</sub> receptor antagonist) at the concentrations of 0.3-100 nM inhibited specific [<sup>125</sup>I]ET-1 binding in the rat bladder in a concentration-dependent manner (Fig. 1), and their  $IC_{50}$  values were 5.75 and 8.41 nM, respectively. Similarly, ambrisentan (ET<sub>A</sub>-selective antagonist) and CI-1020 (ET<sub>A</sub>-selective antagonist) inhibited competitively the bladder [<sup>125</sup>I]ET-1 binding (Fig. 1), with  $IC_{50}$  values of 5.10 and 8.70 nM, respectively.

### Interpretation of result

[<sup>125</sup>I]ET-1 labels selectively ET-1 receptors in rat tissues such as the bladder. Selective antagonists of ET-1 receptors at pharmacological doses may bind to these ET-1 receptors, thereby suggesting some effects on the physiological functions of bladder.

### Concluding message

It is concluded that there exists a significant amount of pharmacologically relevant ET-1 receptors in the rat bladder. Selective antagonists of ET-1 receptors may cause pharmacological effects on the bladder functions. To our knowledge, this study provides the first evidence for the direct identification of pharmacologically relevant ET-1 receptors in the bladder.

Table 1.  $K_d$  and  $B_{max}$  for specific [<sup>125</sup>I]ET-1 binding in the bladder, cerebral cortex, lung, heart, and kidney of rats.

Tissues	$K_d$ (pM)	$B_{max}$ (fmol/mg protein)
Bladder	110 ± 32	272 ± 36
Cerebral cortex	78.4 ± 7.8	172 ± 8
Lung	1607 ± 936	3988 ± 1851
Heart	98.4 ± 14.8	132 ± 9
Kidney	814 ± 236	256 ± 50

Each value represents the mean ± SEM for three to four experiments.




Fig. 1. Competitive inhibition by bosentan, ambrisentan, CI-1020 and ET-1 of specific [<sup>125</sup>I]ET-1 binding in the bladder of rats. Each value represents the mean ± SEM for two to three experiments.

References

1. BJU Int 84: 714-719, 1999
2. J Urol 148: 1290-1298, 1992
3. Eur J Pharmacol 580: 394-400, 2008

Disclosures

**Funding:** None **Clinical Trial:** No **Subjects:** ANIMAL **Species:** Rat **Ethics Committee:** the guidelines for the care and use of laboratory animals of the University of Shizuoka.